HK1232239A1 - 細胞穿透肽及其製造和使用方法 - Google Patents
細胞穿透肽及其製造和使用方法Info
- Publication number
- HK1232239A1 HK1232239A1 HK17105886.7A HK17105886A HK1232239A1 HK 1232239 A1 HK1232239 A1 HK 1232239A1 HK 17105886 A HK17105886 A HK 17105886A HK 1232239 A1 HK1232239 A1 HK 1232239A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- making
- methods
- cell penetrating
- penetrating peptides
- peptides
- Prior art date
Links
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 title 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0039—Coumarin dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
- A61K49/0047—Green fluorescent protein [GFP]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462001535P | 2014-05-21 | 2014-05-21 | |
US201562158351P | 2015-05-07 | 2015-05-07 | |
PCT/US2015/032043 WO2015179691A2 (en) | 2014-05-21 | 2015-05-21 | Cell penetrating peptides and methods of making and using thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1232239A1 true HK1232239A1 (zh) | 2018-01-05 |
Family
ID=54554977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK17105886.7A HK1232239A1 (zh) | 2014-05-21 | 2017-06-14 | 細胞穿透肽及其製造和使用方法 |
Country Status (17)
Country | Link |
---|---|
US (1) | US10626147B2 (zh) |
EP (2) | EP3149025B1 (zh) |
JP (2) | JP6807831B2 (zh) |
CN (2) | CN113861268A (zh) |
CA (1) | CA2949705A1 (zh) |
CY (1) | CY1121953T1 (zh) |
DK (1) | DK3149025T3 (zh) |
ES (1) | ES2739613T3 (zh) |
HK (1) | HK1232239A1 (zh) |
HR (1) | HRP20191254T1 (zh) |
HU (1) | HUE045872T2 (zh) |
LT (1) | LT3149025T (zh) |
PL (1) | PL3149025T3 (zh) |
PT (1) | PT3149025T (zh) |
RS (1) | RS59119B1 (zh) |
SI (1) | SI3149025T1 (zh) |
WO (1) | WO2015179691A2 (zh) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10815276B2 (en) * | 2014-05-21 | 2020-10-27 | Entrada Therapeutics, Inc. | Cell penetrating peptides and methods of making and using thereof |
EP3149025B1 (en) * | 2014-05-21 | 2019-06-26 | Entrada Therapeutics, Inc. | Cell penetrating peptides and methods of making and using thereof |
WO2016033368A1 (en) * | 2014-08-27 | 2016-03-03 | Ohio State Innovation Foundation | Improved peptidyl calcineurin inhibitors |
EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
US11351222B2 (en) | 2016-11-09 | 2022-06-07 | Ohio State Innovation Foundation | Di-sulfide containing cell penetrating peptides and methods of making and using thereof |
US10913773B2 (en) * | 2016-11-22 | 2021-02-09 | Ohio State Innovation Foundation | Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha |
WO2018098282A2 (en) * | 2016-11-22 | 2018-05-31 | Ohio State Innovation Foundation | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof |
TW201825510A (zh) * | 2016-11-22 | 2018-07-16 | 俄亥俄州立創新基金會 | 細胞穿透肽序列 |
CN110603261A (zh) * | 2016-12-23 | 2019-12-20 | 拜斯科阿迪有限公司 | 具有新型键结构的肽衍生物 |
AU2017383008B2 (en) * | 2016-12-23 | 2022-02-17 | Bicycletx Limited | Peptide ligands for binding to MT1-MMP |
JP7301757B2 (ja) | 2017-06-26 | 2023-07-03 | バイスクルアールディー・リミテッド | 検出可能部分を持つ二環式ペプチドリガンドおよびその使用 |
CA3078504A1 (en) | 2017-10-04 | 2019-04-11 | Ohio State Innovation Foundation | Bicyclic peptidyl inhibitors |
CN108070025B (zh) * | 2017-10-24 | 2019-11-19 | 中山大学附属口腔医院 | 一种细胞穿透肽和细胞穿透肽复合物及二者的应用 |
CA3080617A1 (en) | 2017-10-27 | 2019-05-02 | Ohio State Innovation Foundation | Polypeptide conjugates for intracellular delivery of stapled peptides |
GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
WO2019148195A2 (en) * | 2018-01-29 | 2019-08-01 | Ohio State Innovation Foundation | Cyclic peptidyl inhibitors of cal-pdz binding domain |
WO2019148194A2 (en) | 2018-01-29 | 2019-08-01 | Ohio State Innovation Foundation | Peptidyl inhibitors of calcineurin-nfat interaction |
WO2019165183A1 (en) | 2018-02-22 | 2019-08-29 | Entrada Therapeutics, Inc. | Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy |
EP3790890A4 (en) * | 2018-05-09 | 2022-03-02 | Ohio State Innovation Foundation | CYCLIC PEPTIDES OF CELL PENETRATION WITH ONE OR MORE HYDROPHOBIC RESIDUES |
US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
GB201810320D0 (en) * | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to CD38 |
GB201810316D0 (en) * | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
GB201810325D0 (en) * | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to PSMA |
GB201810327D0 (en) * | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to IL-17 |
GB201810329D0 (en) * | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to integrin avB3 |
US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
US20210244824A1 (en) * | 2018-07-02 | 2021-08-12 | Ohio State Innovation Foundation | Polypeptide conjugates for intracellular delivery of nucleic acids |
EP3870600A1 (en) | 2018-10-24 | 2021-09-01 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
GB201900530D0 (en) * | 2019-01-15 | 2019-03-06 | Bicyclerd Ltd | Bicyclic peptide ligands specific for CD38 |
SG11202111606TA (en) | 2019-05-09 | 2021-11-29 | Bicycletx Ltd | Bicyclic peptide ligands specific for ox40 |
TW202110485A (zh) | 2019-07-30 | 2021-03-16 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
CN113105554B (zh) * | 2020-01-13 | 2022-07-26 | 广东泰禾医药科技有限公司 | 一种抗肿瘤融合蛋白及其制法和应用 |
KR20230135586A (ko) | 2021-01-24 | 2023-09-25 | 마이클 데이비드 포레스트 | Atp 합성효소 억제제 - 미용 및 치료 용도 |
KR20240009393A (ko) * | 2021-03-31 | 2024-01-22 | 엔트라다 테라퓨틱스, 인크. | 사이클릭 세포 침투 펩티드 |
WO2022240758A1 (en) * | 2021-05-10 | 2022-11-17 | Entrada Therapeutics, Inc. | Compositions and methods for modulating gene expression |
WO2022240757A1 (en) * | 2021-05-10 | 2022-11-17 | Entrada Therapeutics, Inc. | Antigen-binding and antigen degradation constructs |
JP2024518068A (ja) | 2021-05-10 | 2024-04-24 | エントラーダ セラピューティクス,インコーポレイティド | 細胞内治療のための組成物及び方法 |
WO2023034817A1 (en) * | 2021-09-01 | 2023-03-09 | Entrada Therapeutics, Inc. | Compounds and methods for skipping exon 44 in duchenne muscular dystrophy |
WO2023034818A1 (en) * | 2021-09-01 | 2023-03-09 | Entrada Therapeutics, Inc. | Compositions and methods for skipping exon 45 in duchenne muscular dystrophy |
WO2023081893A1 (en) * | 2021-11-08 | 2023-05-11 | Entrada Therapeutics, Inc. | Intracellular targeting of oligonucleotides |
WO2023178327A1 (en) * | 2022-03-17 | 2023-09-21 | Ohio State Innovation Foundation | Membrane translocation domains and uses thereof |
WO2023205451A1 (en) * | 2022-04-22 | 2023-10-26 | Entrada Therapeutics, Inc. | Cyclic peptides for delivering therapeutics |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965536A (en) | 1993-12-15 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods of inhibiting CXC intercrine molecules |
WO2002064091A2 (en) | 2001-02-13 | 2002-08-22 | Palatin Technologies, Inc. | Melanocortin metallopeptides for treatment of sexual dysfunction |
US6110889A (en) | 1996-06-14 | 2000-08-29 | Board Of Regents, The University Of Texas System | Peptide tumor cell growth inhibitors |
JP3791981B2 (ja) | 1996-10-15 | 2006-06-28 | 森永乳業株式会社 | ペプチド誘導体及び抗真菌剤 |
AU6868898A (en) | 1997-03-20 | 1998-10-12 | Regents Of The University Of California, The | N-methyl-d-aspartate receptor channel blockers and method for identifying such |
CA2224066A1 (en) | 1997-10-24 | 1999-04-24 | Universite D'ottawa/ University Of Ottawa | Peptides as analgesics |
US6388054B1 (en) | 1998-08-20 | 2002-05-14 | John M. Stewart | Anti-cancer compounds |
AU758903B2 (en) | 1998-11-26 | 2003-04-03 | Pentapharm Ag | Transport system conjugate |
EP1177197B1 (en) | 1999-04-30 | 2006-08-09 | Cellgate, Inc. | Polyamines and their use in therapy |
BR0010702A (pt) | 1999-04-30 | 2002-02-13 | Slil Biomedical Corp | Novas quinonas como terapias de doenças |
EP1574507A3 (en) | 1999-04-30 | 2005-10-26 | SLIL Biomedical Corporation | Furo- and pyrano-naphthoquinones and their use in the treatment of cancer |
US6649587B1 (en) | 1999-04-30 | 2003-11-18 | Slil Biomedical Corporation | Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases |
MXPA01011008A (es) | 1999-04-30 | 2003-06-30 | Slil Biomedical Corp | Conjugados analogos de poliamina y conjugados de quinona novedosos como terapia para canceres y enfermedades de la prostata. |
US6482943B1 (en) | 1999-04-30 | 2002-11-19 | Slil Biomedical Corporation | Quinones as disease therapies |
WO2000074701A2 (en) | 1999-06-05 | 2000-12-14 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for inhibiting cardiovascular cell proliferation |
US7229961B2 (en) | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
AU769315B2 (en) | 1999-08-24 | 2004-01-22 | Cellgate, Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
US6730293B1 (en) | 1999-08-24 | 2004-05-04 | Cellgate, Inc. | Compositions and methods for treating inflammatory diseases of the skin |
US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US20020009491A1 (en) | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
US20030072715A1 (en) | 2000-08-02 | 2003-04-17 | Benjamin Frydman | Cyclic polyamine compounds for cancer therapy |
AU7814301A (en) | 2000-08-02 | 2002-02-13 | Slil Biomedical Corp | Cyclic polyamine compounds for cancer therapy |
CA2425610A1 (en) | 2000-10-13 | 2002-04-18 | University Of Lausanne | Intracellular delivery of biological effectors by novel transporter peptide sequences |
US7033597B2 (en) | 2000-10-13 | 2006-04-25 | Université de Lausanne | Intracellular delivery of biological effectors |
US20030167129A1 (en) | 2000-10-27 | 2003-09-04 | Nestor John J. | Binding compounds and methods for identifying binding compounds |
WO2002057313A2 (en) | 2000-10-27 | 2002-07-25 | Consensus Pharmaceuticals, Inc. | Receptor-binding compounds and methods for identifying them |
WO2002091989A2 (en) | 2000-11-08 | 2002-11-21 | Slil Biomedical Corporation | Antiviral therapies using polyamine or polyamine analog-amino acid conjugates |
ATE437647T1 (de) | 2001-02-16 | 2009-08-15 | Cellgate Inc | Transporter mit beabstandeten arginin-teilchen |
WO2002090503A2 (en) | 2001-05-04 | 2002-11-14 | The Scripps Research Institute | Anti-microbial peptides and compositions |
CA2455951A1 (en) | 2001-08-03 | 2003-02-20 | The Board Of Trustees Of The Leland Stanford Junior University | Bi-directional synthesis of oligoguanidine transport agents |
EP1436246A1 (en) | 2001-10-16 | 2004-07-14 | SLIL Biomedical Corporation | Oligoamine compounds and derivatives thereof for cancer therapy |
US7052877B2 (en) | 2001-11-30 | 2006-05-30 | Applera Corporation | Thermus brockianus nucleic acid polymerases |
AU2002364539A1 (en) | 2001-12-07 | 2003-06-23 | Cellgate, Inc. | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor |
EP1461084A2 (en) | 2001-12-11 | 2004-09-29 | The Board Of Trustees Of The Leland Stanford Junior University | Guanidinium transport reagents and conjugates |
SI1483290T1 (sl) * | 2002-01-17 | 2009-02-28 | Takeda Pharmaceutical | Peptidi in peptidomimetiki, ki imajo antiproliferacijsko aktivnost in/ali okrepijo sredstva ali obdelave, ki poškodujejo nukleinsko kislino |
FR2836474B1 (fr) | 2002-02-22 | 2004-12-24 | Synt Em | Composes, compositions et methode pour le transport des molecules de cyclosporine a travers la barriere hemato-encephalique |
AU2003241384A1 (en) | 2002-05-06 | 2003-11-17 | The Scripps Research Institute | Cyclic peptide anti-viral agents and methods |
AU2003232077A1 (en) | 2002-05-06 | 2003-11-17 | The Scripps Research Institute | Cyclic peptide anti-cancer agents and methods |
AU2003279756A1 (en) | 2002-06-26 | 2004-01-19 | Cellgate, Inc. | Porphyrin-polyamine conjugates for cancer therapy |
US20040192665A1 (en) | 2002-08-02 | 2004-09-30 | Slil Biomedical Corporation | Conjugates of porphyrin compounds with chemotherapeutic agents |
US20060128614A1 (en) | 2002-09-20 | 2006-06-15 | Jya-Wei Cheng | Antimicrobial peptides with reduced hemolysis and methods of their use |
AU2003297657A1 (en) | 2002-11-29 | 2004-06-23 | Adaptive Therapeutics, Inc. | Antifungal therapeutic agents |
US20090123468A1 (en) | 2003-10-24 | 2009-05-14 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
EP1737482A4 (en) | 2004-03-01 | 2010-09-15 | Lumen Therapeutics Llc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES |
AU2005294514A1 (en) | 2004-10-04 | 2006-04-20 | Cellgate, Inc. | Polyamine analogs as therapeutic agents for ocular diseases |
US20090143456A1 (en) | 2005-02-11 | 2009-06-04 | Marton Laurence J | Polyamine Analogs as Modulators of Cell Migration and Cell Motility |
WO2007040535A1 (en) | 2005-10-03 | 2007-04-12 | Cellgate, Inc. | Use of polyamine analogs for treatment and prevention of intestinal polyps |
WO2007055578A1 (en) | 2005-11-11 | 2007-05-18 | Leids Universitair Medisch Centrum | Cyclic antimicrobial peptides derived from lactoferrin |
US20080090760A2 (en) | 2005-12-09 | 2008-04-17 | Todd Hembrough | Compositions and Methods for Inhibiting Cellular Proliferation |
WO2007072037A1 (en) | 2005-12-22 | 2007-06-28 | Novabiotics Limited | Cyclic antimicrobial peptides |
US9181303B2 (en) | 2005-12-22 | 2015-11-10 | Novabiotics Limited | Treatment of bacterial infections with cyclic antimicrobial peptides |
WO2007097561A1 (en) * | 2006-02-20 | 2007-08-30 | Ewha University - Industry Collaboration Foundation | Peptide having cell membrane penetrating activity |
JP5308829B2 (ja) | 2006-02-27 | 2013-10-09 | テクニッシュ ユニべルシタット ミュンヘン | 癌の画像化および処置 |
WO2007106554A2 (en) | 2006-03-14 | 2007-09-20 | Progen Pharmaceuticals, Inc. | Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds |
US20100279918A1 (en) | 2006-03-20 | 2010-11-04 | Burnham Institute For Medical Research | Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents |
WO2007111993A2 (en) | 2006-03-22 | 2007-10-04 | Cellgate, Inc. | Polyamine analogs as therapeutic agents for skin diseases |
WO2008077194A1 (en) | 2006-12-22 | 2008-07-03 | Xenome Ltd | Receptor agonists |
GB0702020D0 (en) | 2007-02-02 | 2007-03-14 | Novabiotics Ltd | Peptides and their use |
GB0716897D0 (en) | 2007-08-30 | 2007-10-10 | Univ Muenchen Tech | Cancer imaging and treatment |
EP3320923B1 (en) | 2008-01-18 | 2022-04-06 | Visen Medical, Inc. | Fluorescent imaging agents |
WO2010107832A1 (en) | 2009-03-17 | 2010-09-23 | Bracco Imaging Spa | Lhrh-ii peptide analogs |
ES2570458T3 (es) | 2010-02-05 | 2016-05-18 | Polyphor Ag | Peptidomiméticos fijados sobre una matriz con actividad moduladora de CXCR7 |
WO2011095218A1 (en) | 2010-02-05 | 2011-08-11 | Polyphor Ag | Template-fixed pep tidomime tics with cxcr7 modulating activity |
WO2011126010A1 (ja) * | 2010-04-06 | 2011-10-13 | 三菱化学株式会社 | 癌細胞選択的膜透過性ペプチドおよびその利用 |
JP2012131743A (ja) * | 2010-12-22 | 2012-07-12 | Kyoto Univ | 腫瘍集積型抗癌剤 |
WO2013142184A1 (en) | 2012-03-19 | 2013-09-26 | Yale University | Antimicrobial compositions and methods |
WO2014053882A1 (en) * | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
US20150038671A1 (en) | 2013-05-30 | 2015-02-05 | Keykavous Parang | Efficient Synthesis of CN2097 and RC7 and Their Analogs |
US20170112896A1 (en) | 2014-05-20 | 2017-04-27 | Ohio State Innovation Foundation | Small molecule rac or rho inhibitors |
EP3149025B1 (en) | 2014-05-21 | 2019-06-26 | Entrada Therapeutics, Inc. | Cell penetrating peptides and methods of making and using thereof |
US10815276B2 (en) | 2014-05-21 | 2020-10-27 | Entrada Therapeutics, Inc. | Cell penetrating peptides and methods of making and using thereof |
EP3166959A4 (en) | 2014-07-11 | 2017-12-13 | C3 Jian, Inc. | Targeting peptides that bind s. mutans, constructs comprising such peptides and uses thereof |
WO2016033368A1 (en) | 2014-08-27 | 2016-03-03 | Ohio State Innovation Foundation | Improved peptidyl calcineurin inhibitors |
EP3194422B1 (en) | 2014-09-19 | 2020-04-29 | Tensive Controls, Inc. | Anti-microbial peptides |
JP2016065018A (ja) | 2014-09-25 | 2016-04-28 | 国立大学法人京都大学 | Cxcr7結合剤およびcxcr7結合剤を含有する医薬組成物 |
CN105440105B (zh) | 2015-12-17 | 2018-11-27 | 倪京满 | 一种具有高稳定性及抗耐药活性的组合抗菌肽的制备和应用 |
-
2015
- 2015-05-21 EP EP15796259.8A patent/EP3149025B1/en active Active
- 2015-05-21 CN CN202110807512.9A patent/CN113861268A/zh active Pending
- 2015-05-21 CN CN201580034608.9A patent/CN106852146B/zh active Active
- 2015-05-21 RS RS20190977A patent/RS59119B1/sr unknown
- 2015-05-21 PT PT15796259T patent/PT3149025T/pt unknown
- 2015-05-21 LT LTEP15796259.8T patent/LT3149025T/lt unknown
- 2015-05-21 EP EP19182012.5A patent/EP3613426A1/en active Pending
- 2015-05-21 HU HUE15796259A patent/HUE045872T2/hu unknown
- 2015-05-21 DK DK15796259.8T patent/DK3149025T3/da active
- 2015-05-21 SI SI201530819T patent/SI3149025T1/sl unknown
- 2015-05-21 JP JP2017513613A patent/JP6807831B2/ja active Active
- 2015-05-21 US US15/312,878 patent/US10626147B2/en active Active
- 2015-05-21 PL PL15796259T patent/PL3149025T3/pl unknown
- 2015-05-21 ES ES15796259T patent/ES2739613T3/es active Active
- 2015-05-21 CA CA2949705A patent/CA2949705A1/en active Pending
- 2015-05-21 WO PCT/US2015/032043 patent/WO2015179691A2/en active Application Filing
-
2017
- 2017-06-14 HK HK17105886.7A patent/HK1232239A1/zh unknown
-
2019
- 2019-07-12 HR HRP20191254TT patent/HRP20191254T1/hr unknown
- 2019-07-30 CY CY20191100816T patent/CY1121953T1/el unknown
-
2020
- 2020-04-14 JP JP2020072542A patent/JP2020169170A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2020169170A (ja) | 2020-10-15 |
CN106852146A (zh) | 2017-06-13 |
EP3149025B1 (en) | 2019-06-26 |
US20170190743A1 (en) | 2017-07-06 |
CY1121953T1 (el) | 2020-10-14 |
PL3149025T3 (pl) | 2019-11-29 |
EP3613426A1 (en) | 2020-02-26 |
HUE045872T2 (hu) | 2020-01-28 |
RS59119B1 (sr) | 2019-09-30 |
CN106852146B (zh) | 2021-08-13 |
EP3613426A9 (en) | 2023-05-24 |
LT3149025T (lt) | 2019-09-25 |
EP3149025A4 (en) | 2018-02-21 |
PT3149025T (pt) | 2019-08-01 |
WO2015179691A2 (en) | 2015-11-26 |
ES2739613T3 (es) | 2020-02-03 |
US10626147B2 (en) | 2020-04-21 |
CA2949705A1 (en) | 2015-11-26 |
EP3149025A2 (en) | 2017-04-05 |
CN113861268A (zh) | 2021-12-31 |
SI3149025T1 (sl) | 2019-09-30 |
JP2017519041A (ja) | 2017-07-13 |
WO2015179691A9 (en) | 2016-03-31 |
DK3149025T3 (da) | 2019-07-22 |
JP6807831B2 (ja) | 2021-01-06 |
HRP20191254T1 (hr) | 2019-10-18 |
WO2015179691A3 (en) | 2016-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1232239A1 (zh) | 細胞穿透肽及其製造和使用方法 | |
HK1250481A1 (zh) | 經過修飾的t細胞及其製備和使用方法 | |
HK1243102A1 (zh) | 抗cd79b抗體和使用方法 | |
HRP20181359T1 (hr) | Anti-jagged1 protutijela i postupci uporabe | |
IL251868A0 (en) | Anti-tim3 antibodies and methods of use | |
IL250415B (en) | Antibodies against pd-l and methods of using them | |
IL251165A0 (en) | Anti-il-1beta antibodies and methods of their use | |
IL251286A0 (en) | Anti-pdgf-b antibodies and methods of use | |
GB201419472D0 (en) | Method of using and electrochemical device | |
IL247448A0 (en) | Peptides and methods of use | |
GB201403107D0 (en) | Permeability and transformation of cells | |
AU2014901577A0 (en) | Thermo-Electrochemical Cell and Method of Use |